179 related articles for article (PubMed ID: 36509945)
1. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
Alegre A; Benzo G; Alonso R; Martínez-López J; Jimenez-Ubieto A; Cuéllar C; Askari E; Prieto E; Aláez C; Aguado B; Velasco A; Krsnik I; Bocanegra A; Llorente L; Muñoz-Linares C; Morales A; Giménez E; Iglesias R; Martínez-Chamorro C; Alonso A; Jiménez-Montes C; Blanchard MJ;
Oncol Ther; 2023 Mar; 11(1):83-96. PubMed ID: 36509945
[TBL] [Abstract][Full Text] [Related]
2. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
de la Rubia J; Alonso R; Clavero ME; Askari E; García A; Antón C; Fernández M; Escalante F; García A; Rios-Tamayo R; Conesa V; Bermúdez MA; Merchán B; Velasco AE; Blanchard MJ; Sampol A; Gainza E; Hernández PM; Alegre A
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296925
[TBL] [Abstract][Full Text] [Related]
3. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Talbot A; Bobin A; Tabone L; Lambert J; Boccaccio C; Deal C; Petillon MO; Allangba O; Agape P; Arnautou P; Belkhir R; Cailleres S; Chaoui D; Chrétien ML; Decaux O; Schulmann S; Frenzel L; Gastaud L; Huart A; Hulin C; Karlin L; Laribi K; Le Calloch R; Lenain P; Macro M; Manier S; Montes L; Moreau S; Moreau P; Morel V; Norwood J; Piocelle FO; Perrot A; Pica GM; Rey P; Schmitt A; Stoppa AM; Tiab M; Touzeau C; Vidal V; Vignon M; Vincent L; Van De Wyngaert Z; Zarnitsky C; Kerbouche N; Paka P; Leleu X; Arnulf B; Avet-Loiseau H; Du Myélome IIF
Haematologica; 2023 Oct; 108(10):2774-2782. PubMed ID: 37078253
[TBL] [Abstract][Full Text] [Related]
4. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
Shragai T; Magen H; Lavi N; Gatt M; Trestman S; Zektser M; Ganzel C; Jarchowsky O; Berger T; Tadmor T; Leiba M; Hertzog-Tzarfaty K; Horowitz N; Shapira M; Varssano D; Berger Y; Frenkel S; Krauthammer M; Avivi I; Luttwak E; Cohen YC;
Br J Haematol; 2023 Jan; 200(1):45-53. PubMed ID: 36205375
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.
Iula R; De Novellis D; Trastulli F; Della Pepa R; Fontana R; Carobene A; Di Perna M; D'Ambrosio A; Romano M; Leone A; De Fazio L; Fiumarella A; Gaeta G; Marafioti V; Barbato S; Palmieri S; Rocco S; Serio B; Califano C; Pane F; Ferrara F; Giudice V; Selleri C; Catalano L
Front Oncol; 2022; 12():1026251. PubMed ID: 36457484
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study.
Roussel M; Texier N; Nael V; Bitetti J; Paka P; Kerbouche N; Sail L; Colin X; Leleu X
Eur J Haematol; 2024 May; ():. PubMed ID: 38722078
[TBL] [Abstract][Full Text] [Related]
7. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
[TBL] [Abstract][Full Text] [Related]
8. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
[TBL] [Abstract][Full Text] [Related]
10. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
[TBL] [Abstract][Full Text] [Related]
11. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Spiliopoulou V; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511588
[TBL] [Abstract][Full Text] [Related]
12. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
13. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
[TBL] [Abstract][Full Text] [Related]
14. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
[TBL] [Abstract][Full Text] [Related]
15. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
Becnel MR; Lee HC
Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
[TBL] [Abstract][Full Text] [Related]
16. Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma.
Atieh T; Atrash S; Ahmed N; Mohan M; Cui W; Shune L; Hajjar S; Mahmoudjafari Z; Quick J; Wishna A; Riffel J; McGuirk J; Mohyuddin GR; Abdallah AO
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):912-919. PubMed ID: 36127271
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
Popat R; Lonial S; Voorhees PM; Esposti SD; Gorsh B; Gupta I; Opalinska J; Sapra S; Piontek T; He Z; Kleinman D; Schaumberg D; Regnault A; Meunier J; Eliason L
J Adv Pract Oncol; 2023 Sep; 14(6):503-518. PubMed ID: 37808071
[TBL] [Abstract][Full Text] [Related]
18. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
19. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
Front Oncol; 2021; 11():678634. PubMed ID: 34046363
[TBL] [Abstract][Full Text] [Related]
20. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
Neupane K; Wahab A; Masood A; Faraz T; Bahram S; Ehsan H; Hannan A; Anwer F
J Blood Med; 2021; 12():529-550. PubMed ID: 34234609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]